MA11.02 Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib

Although pharmacologic agents targeting driver mutations in lung adenocarcinoma have led to tremendous clinical benefits for patients, human epidermal growth factor receptor 2 (HER2)-activating mutations do not have therapeutic agents and still represent an unmet clinical need. Mobocertinib is a potent tyrosine kinase inhibitor designed to target epidermal growth factor receptor (EGFR) and HER2 exon 20 insertion mutations and has reported activity in the clinic in patients with EGFR exon 20 insertionmutant non–small cell lung cancer (NSCLC).